2022
“Near Cure” treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct
Vandenbark AA, Meza-Romero R, Wiedrick J, Gerstner G, Seifert H, Kent G, Piechycna M, Benedek G, Bucala R, Offner H. “Near Cure” treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct. Cellular Immunology 2022, 378: 104561. PMID: 35738135, PMCID: PMC9714992, DOI: 10.1016/j.cellimm.2022.104561.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisAcute experimental autoimmune encephalomyelitisDRα1-MOG-35Multiple sclerosisMIF-1EAE scoresMale miceMIF-2Severe diseaseMacrophage migration inhibitory factorClinical EAE scoresMIF-deficient micePeripheral inflammatory cellsMigration inhibitory factorSpinal cord tissueT cell activationSex-dependent differencesEAE severityAutoimmune encephalomyelitisSerum levelsTreatment of WTInflammatory cellsFemale miceClinical signsCord tissue
2006
Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes
Tan K, Chow W, Shiu S, Bucala R, Betteridge D. Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes. Atherosclerosis Plus 2006, 7: 294. DOI: 10.1016/s1567-5688(06)81196-7.Peer-Reviewed Original Research